TB006
Sponsors
TrueBinding, Inc., Rossignol Medical Center
Conditions
Acute Ischemic StrokeAlzheimer DiseaseAlzheimer's DiseaseAutism Spectrum DisorderCovid19Parkinson's Disease (PD)
Phase 1
Study of TB006 in Outpatient Patients With Mild to Moderate COVID-19
WithdrawnNCT04801056
Start: 2021-06-01End: 2021-09-01Updated: 2022-05-18
Sequential Dose-escalation Study to Assess the Safety, Tolerability and Pharmacokinetics of TB006 in Healthy Subjects
CompletedNCT04920786
Start: 2021-06-01End: 2022-05-03Updated: 2024-12-09
Study to Assess the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Efficacy of TB006 in Participants With Alzheimer's Disease
CompletedNCT05074498
Start: 2021-10-08End: 2022-10-13Updated: 2023-11-18
Phase 2
A Study to Assess the Efficacy, Safety, and Pharmacokinetics of TB006 in Participants With Acute Ischemic Stroke
WithdrawnNCT05156827
Start: 2022-07-26End: 2023-12-18Updated: 2024-01-12
A Long Term Extension Study to Assess the Safety of TB006 in Participants With Alzheimer's Disease
TerminatedNCT05476783
Start: 2022-09-15End: 2023-11-17Updated: 2026-05-06
TB006 for Autism Spectrum Disorder
RecruitingNCT06500637
Start: 2024-08-03End: 2027-01-31Target: 45Updated: 2026-04-14
A Phase 2a Multicenter Clinical Trial of TB006 in Participants With Parkinson's Disease
Active, not recruitingNCT06773962
Start: 2025-03-20End: 2026-11-28Target: 62Updated: 2026-04-23